These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7517611)

  • 1. Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
    Lindström E; von Knorring L
    Acta Psychiatr Scand; 1994 Apr; 89(4):274-8. PubMed ID: 7517611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
    Lindström E; von Knorring L
    Pharmacopsychiatry; 1994 May; 27(3):108-13. PubMed ID: 7521534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
    von Knorring L; Lindström E
    Acta Psychiatr Scand; 1992 Dec; 86(6):463-8. PubMed ID: 1281960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
    Wilms G; Van Ongeval C; Baert AL; Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):306-12. PubMed ID: 1375802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative symptoms in schizophrenia: assessment of the effect of risperidone.
    Schooler NR
    J Clin Psychiatry; 1994 May; 55 Suppl():22-8. PubMed ID: 7520905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
    Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):295-305. PubMed ID: 1375801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
    Addington DE; Jones B; Bloom D; Chouinard G; Remington G; Albright P
    Clin Ther; 1993; 15(5):917-26. PubMed ID: 7505716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone treatment for severe negative symptoms.
    Jones BD; Purdon SE; Labelle A; Finlayson R
    Can J Psychiatry; 1994 Aug; 39(6):381. PubMed ID: 7527292
    [No Abstract]   [Full Text] [Related]  

  • 13. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 14. [Symptomatic remission and its relationship to social functioning in Tunisian out-patients with schizophrenia].
    El Gharbi I; Chhoumi M; Mechri A
    Encephale; 2019 Feb; 45(1):15-21. PubMed ID: 29195805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review of risperidone.
    Chouinard G; Arnott W
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S89-95. PubMed ID: 7504574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone in adolescents.
    Cozza SJ; Edison DL
    J Am Acad Child Adolesc Psychiatry; 1994 Oct; 33(8):1211. PubMed ID: 7527022
    [No Abstract]   [Full Text] [Related]  

  • 17. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of the newer antipsychotic drugs.
    Perry PJ
    Am J Health Syst Pharm; 1995 Feb; 52(3 Suppl 1):S9-14. PubMed ID: 7538437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
    Sharma RP; Dowd SM; Davis JM; Janicak PG
    Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy.
    Peralta V; de Leon J; Cuesta MJ
    Br J Psychiatry; 1992 Sep; 161():335-43. PubMed ID: 1356572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.